Rezolve-Ad Phase 2B Study Of Rezpegaldesleukin Meets Primary And Key Secondary Endpoints In Patients With Moderate-To-Severe Atopic Dermatitis
June 24 (Reuters) - Nektar Therapeutics NKTR.O:
REZOLVE-AD PHASE 2B STUDY OF REZPEGALDESLEUKIN MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
NEKTAR THERAPEUTICS - REZOLVE-AD PHASE 2B STUDY MEETS PRIMARY AND KEY SECONDARY ENDPOINTS
NEKTAR THERAPEUTICS - ACHIEVED STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT AT WEEK 16
NEKTAR THERAPEUTICS - SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED RESULTS
NEKTAR THERAPEUTICS: DATA EXPECTED IN Q1 2026 FROM TREATMENT OF PATIENTS WITH ATOPIC DERMATITIS IN LONG-TERM MAINTENANCE PART OF REZOLVE-AD STUDY
NEKTAR THERAPEUTICS -TOP-LINE PHASE 2B DATA FOR REZPEGALDESLEUKIN IN ALOPECIA AREATA EXPECTED IN Q4 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Precious Metals May Outlook: After U.S.-Iran Conflict Concerns Eased, Will Funds Flow Back to Gold and Silver?

Is SanDisk the Hidden Gem of the AI Boom in 2026? Discover the Potential Risks and Rewards.

Intel vs. TSM: Which Semiconductor Stock Looks Like the Better Investment?

What Is Intel, and Is Its Stock Still a Worthwhile Investment?

Amazon vs. Microsoft: Which Stock Is a Better Buy for 2026 and Beyond?

Tradingkey








